To further investigate the role of CD204 involved in the TIME of breast cancer, we first explored the correlations between CD204 and TIME-related immunoinhibitors among luminal A, B, HER-2-enriched, and basal-like subtypes (Figure 7B). This evidence concerns the gene ERBB2 and breast carcinoma.